The plasma-derived medicine maker plans to create 1,500 jobs to support one of the state’s largest private biomedical investments.
An article from
Dive Brief
The plasma-derived medicine maker plans to create 1,500 jobs to support one of the state’s largest private biomedical investments.
Published Aug. 3, 2026
An architectural rendering of Palmetto Research Park in Rockhill, South Carolina. Octapharma plans to invest $1.5 billion on its first U.S. biomedical manufacturing facility at the industrial park.
South Korean contract manufacturer Samsung Biologics hopes to tap into the booming peptide production and weight loss market with…
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
South Korean biopharmaceutical company Celltrion said it would invest at least $1 billion to acquire a plant from Eli Lilly in…
Samsung Biologics offers $1.8B for Swiss CDMO PolyPeptide, expanding beyond biologics into peptide APIs and the booming GLP-1…
As the recent reshoring zeal rolls on in the United States, BeOne Medicines is beefing up its flagship manufacturing and R&D…
(Bloomberg) -- Samsung Biologics Co. agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the…
